New Report Covers Global Myasthenia Gravis Drugs Market 2017-2021

Report : Global Myasthenia Gravis Drugs Market 2017-2021 is a new market research publication announced by Reportstack. 

Report Outline: Currently, the myasthenia gravis drugs market stands at a small size due to limited availability of approved therapies for the complete remission of the disease. However, the anticipated approval of novel drugs such as monoclonal antibodies should help market witness strong growth during the forecast period. For instance, Alexion Pharmaceuticals is currently developing a monoclonal antibody, Soliris, for the treatment of myasthenia gravis. Once launched around end 2017 or beginning of 2018, this drug is expected to be the blockbuster drug for the market.

For detailed report with TOC, please click here ​Global Myasthenia Gravis Drugs Market 2017-2021

Market Growth: The global myasthenia gravis drugs market to grow at a CAGR of 13.16% during the period 2017-2021.

Key vendors • Flamel Technologies
• F. Hoffmann-La Roche
• Grifols
• Pfizer
• Shire
• Valeant Pharmaceuticals

Other prominent vendors • Alexion Pharmaceuticals
• Catalyst Pharmaceuticals
• CSL
• Curavac
• Cytokinetics
• Galencia
• GlaxoSmithKline
• Lupin Pharmaceuticals
• Mitsubishi Tanabe Pharma
• Novartis

Regions Covered:

• Americas
• APAC
• EMEA

Companies Mentioned

Flamel Technologies, F. Hoffmann-La Roche, Grifols, Pfizer, Shire, Valeant Pharmaceuticals, Alexion Pharmaceuticals, Catalyst Pharmaceuticals, CSL, Curavac, Cytokinetics, Galencia, GlaxoSmithKline, Lupin Pharmaceuticals, Mitsubishi Tanabe Pharma, Novartis.

Contact:

Debora White

Manager - Marketing

debora@reportstack.com

Ph: +1-888-789-6604

Reportstack Market Research

###